Table 2.
Protective heat shock protein (HSP) peptide treatment in experimental models of autoimmunity
| Model | Route | Adjuvant | Regimen | Peptides | HSP | References | |
|---|---|---|---|---|---|---|---|
| Arthritis | DIA | i.d. | IFA | p | Mixture of 120–134 and 213–277 | Self | Moudgil, J Immunol 2005 |
| PIA | i.p. | None | p and t | 261–271 | Non-self | Thompson, J Immunol 1998; Francis, Immunology 2000 | |
| AA and CPIA | i.d. | DDA | p | 256–270 | Non-self | Anderton, J Exp Med 1995 | |
| AA and AIA | i.n. | None | p | 176–190 | Non-self | Prakken, Proc Natl Acad Sci 1997 | |
| AA | i.d. | IFA | p | 180–188 | Non-self | Golden, Agents Actions 1991 | |
| AA | i.n. | None | t | 180–188 | Non-self | Roord, PLoS ONE 2006 | |
| AA | i.d. | IFA | p | 234–252 | Non-self | Tanaka, J Immunol 1999 | |
| AA | i.n. | None | p | 111–125 | Non-self | Wendling, J Immunol 2000 | |
| AA | i.p. | None | p | 61–80 (mHSP65), 31–46, 37–52 (self)HSP60 | Both | Ulmansky, J Immunol 2002 | |
| AA | i.n. | None | p | 254–268 | Non-self | Zonneveld-Huijssoon, Ann Rheum Dis 2011 | |
| AA | s.c. | DDA | p | Mixture of 417–431, 441–455, 465–479, 513–527, 521–535 (BCTD) | Non-self | Moudgil, J Exp Med 1997; Durai, J Immunol 2004 | |
| AA | s.c. | IFA | p | 177–191 | Non-self | Durai, J Rheumatol 2007 | |
| DM | NOD | s.c. | IFA | t | 437–460 (p277) | Self | Cohen, Lancet 1994 |
| NOD | i.p. | IFA | p and t | 437–460 (p277) | Self | Elias, Diabetes 1995, 1997; Ablamunits, J Autoimmun 1998; Tian, J Immunol 1998; Elia, Proc Natl Acad Sci 1991 | |
| STZ | i.p. | Mineral oil | t | 437–460 (p277) | Self | Elias, Diabetes 1996 | |
| NOD | s.c. | IFA | p | 166–185 (p12) | Self | Elias, J Autoimmun 1997 | |
| BB-DP | p.o. | None | p | Peptide analogue of p277 (Diapep277) | Self | Brugman, Diabetologia 2004 | |
| Sjögren | SS | s.c. | IFA | p | 437–460 | Self | Delaleu, Arthritis Rheum 2008 |
Adapted from [12] and [22]. AA: adjuvant arthritis; DIA: dimethyl dioctadecyl ammoniumbromide-induced arthritis; PIA: pristine-induced arthritis; AIA: avridine-induced arthritis; CPIA: CP20961-induced arthritis; STZ: STZ toxin-induced diabetes; BB-DP: BioBreeding-Diabetes Prone rat; SS: spontaneous Sjögren syndrome; i.d.: intradermal; i.p.: intraperitoneal; i.n.: intranasal; s.c.: subcutaneous; p.o.: per os, oral; IFA: incomplete Freund's adjuvant; DDA: dimethyl dioctadecyl ammoniumbromide; p: preventive regimen; t: therapeutic regimen.